BCL-2 (B-cell lymphoma 2) Inhibitors Market by Product, Type, and Geography - Forecast and Analysis 2023-2027

Published: Feb 2023 Pages: 166 SKU: IRTNTR72723

The BCL-2 (b-cell lymphoma 2) inhibitors market is estimated to grow at a CAGR of 12.92% between 2022 and 2027. The size of the market is forecast to increase by USD 1,657.08 million. The growth of the market depends on serval factors, including the rising geriatric population, growing awareness about hematological malignancies, and high target affinity and specificity of BCL-2 inhibitors.

This report extensively covers market segmentation by product (combination therapy and monotherapy), type (diffuse large b-cell lymphoma (DLNCL), follicular lymphoma, chronic lymphocytic leukemia, and mantle cell lymphoma (MCL)), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the size of the BCL-2 (B-cell Lymphoma 2) Inhibitors Market During the Forecast Period?

To learn more about this report, Download Report Sample

Parent Market Analysis

The reports categorize the global BCL-2 inhibitors market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent global pharmaceuticals market covers products and companies engaged in R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Our research report has extensively covered external factors influencing the parent market growth during the forecast period.

BCL-2 (B-cell Lymphoma 2) Inhibitors Market: Key Drivers, Trends, Challenges, and Customer Landscape

The rise in the geriatric population is notably driving the b-cell lymphoma 2 inhibitors market growth, although factors such as the availability of substitutes may impede the market growth.  Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key BCL-2 (B-cell Lymphoma 2) Inhibitors Market Driver

The rise in the geriatric population is one of the key drivers supporting the BCL-2 inhibitors market growth. According to the Centers for Disease Control and Prevention (CDC), the US geriatric population is expected to increase to 19.6% in 2030, while it was approximately 2.4% in 2000. The population of adults aged 80 years and above in the US was approximately 9.3 million in 2000, and it is expected to reach 19.5 million by 2030.

As the geriatric population is an important sub-group that is more likely to be affected by indications such as CLL/SLL and AML in comparison to the young adult population, the market is expected to witness an increase in the patient population. Thus, as the geriatric population has been increasing globally, the patient pool for indications such as CLL/SLL and AML is expected to grow, thereby contributing to the growth of the global BCL-2 inhibitors market growth during the forecast period.

Significant BCL-2 (B-cell Lymphoma 2) Inhibitors Market Trend

Growing approval of combination therapy is the key trend in the b-cell lymphoma 2 inhibitors market. The market growth is driven mainly by the label expansion of venetoclax combination therapy and the advantages of combination therapy. For instance, in 2021, the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Venclexta (venetoclax) in combination with azacitidine.

Similarly, in March 2021, venetoclax in combination with azacitidine or LDAC was approved in Japan. Thus, the rising global acceptance of venetoclax combination therapy will drive market growth during the forecast period.

Major BCL-2 (B-cell Lymphoma 2) Inhibitors Market Challenge

The availability of substitutes is one of the factors hindering the b-cell lymphoma 2 inhibitors market growth. For instance, biologics have minimum to negligible adverse effects. Chemotherapy, radiation therapy, and surgery have a strong adoption in the treatment landscape. Meanwhile, leukapheresis is a procedure in which white blood cells, along with leukemia cells, are removed to ease normal circulation and prevent heart failure and respiratory problems before the chemotherapy drugs are administered. These substitutes aim to remove all cancerous cells, which largely renders these therapies remissive.

The curative nature of these alternatives, along with lesser side effects, render them popular substitutes for treatments, such as chemotherapy, including BCL-2 inhibitors. Thus, advances in and the availability of alternative therapies are expected to be among the major barriers to the growth of the global BCL-2 inhibitors market during the forecast period.

Key BCL-2 (B-cell Lymphoma 2) Inhibitors Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global BCL-2 (B-cell lymphoma 2) Inhibitors Market Customer Landscape

Who are the Major BCL-2 (B-cell lymphoma 2) Inhibitors Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

AbbVie Inc. - The company operates under one segment. Under this segment, the company conducts research and development, manufacturing, commercialization, and sale of innovative medicines and therapies to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. The company offers BCL-2 (B-cell lymphoma 2) inhibitor namely S55746 as its key offering.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

  • Abcam plc
  • Amgen Inc.
  • Ascentage Pharma Group International
  • AstraZeneca Plc
  • BeiGene Ltd.
  • Bio Techne Corp.
  • Biorbyt Ltd.
  • Bristol Myers Squibb Co.
  • F. Hoffmann La Roche Ltd.
  • Ipsen Pharma
  • Merck and Co. Inc.
  • Novartis AG
  • Santa Cruz Biotechnology Inc.
  • Seagen Inc.
  • Servier

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the BCL-2 (B-cell Lymphoma 2) Inhibitors Market?

The market share growth of the combination therapy segment will be significant during the forecast period. Combination therapy was the largest segment of the global BCL-2 inhibitors market in 2021. The growth of this segment is mainly driven by the label expansion of venetoclax from monotherapy to combination therapy and the advantages of combination therapy over monotherapy. The combination therapy using venetoclax has high efficacy and tolerability compared with monotherapy.

Get a glance at the market contribution of various segments Request a PDF Sample

The combination therapy segment was valued at USD 980.92 million in 2017 and continued to grow until 2021. The segment of the BCL-2 inhibitors market is growing rapidly due to the increasing incidence of cancer, the availability of new drugs, and the high demand for effective cancer treatments, which, in turn, will contribute to the growth of the global BCL-2 inhibitors market during the forecast period.

Which are the Key Regions for the BCL-2 (B-cell Lymphoma 2) Inhibitors Market?

For more insights on the market share of various regions Request PDF Sample now!

North America is estimated to contribute 55% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

The growth of the market in the region is driven by the recent approvals of venetoclax combinations in the US. For instance, in 2021, the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Venclexta (venetoclax) in combination with azacitidine. This type of special regulatory designation encourages companies to expand drug development for other diseases as well. Venetoclax was jointly developed and commercialized by AbbVie and Roche in the US and by AbbVie outside the US. Moreover, in the US, approximately 10,000 people are diagnosed with myelodysplastic syndromes (MDS) every year, and therefore, there is a high unmet need for new treatment options. Vendors in the region are working on clinical trials to introduce new therapies in the region to meet the demand. For instance, Abbvie is working on a number of combination therapies that are currently in clinical trials, such as navitoclax in combination with ruxolitinib, which is in the phase 2 study. Thus, the expected approval of venetoclax combination therapy will drive market growth in the region during the forecast period.

In 2020, the outbreak of COVID-19 negatively impacted the growth of the regional BCL-2 inhibitors market in 2020. However, in 2021, several business and industrial activities resumed owing to large-scale vaccination drives, which increased the demand for BCL-2 inhibitors. Furthermore, the increasing demand for new and innovative drugs, the growing focus on personalized medicines, and the development of companion diagnostics are expected to increase the demand for BCL-2 inhibitors in the region. Such factors are anticipated to drive the growth of the regional market during the forecast period. 

Segment Overview

The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

  • Product Outlook (USD Million, 2017 - 2027)
    • Combination therapy
    • Monotherapy
  • Type Outlook (USD Million, 2017 - 2027)
    • Diffuse large B-cell lymphoma (DLBCL)
    • Follicular lymphoma
    • Chronic lymphocytic leukemia
    • Mantle cell lymphoma (MCL)
  • Region Outlook (USD Million, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of World (ROW)
      • Brazil
      • Argentina
      • Rest of the Middle East & Africa

BCL-2 (B-cell Lymphoma 2) Inhibitors Market Scope

Report Coverage

Details

Page number

166

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 12.92%

Market growth 2023-2027

USD 1,657.08 million

Market structure

Concentrated

YoY growth 2022-2023(%)

12.25

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 55%

Key countries

US, Canada, Germany, UK, and France

Competitive landscape

 Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Abcam plc, Amgen Inc., Ascentage Pharma Group International, AstraZeneca Plc, BeiGene Ltd., Bio Techne Corp., Biorbyt Ltd., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Ipsen Pharma, Merck and Co. Inc., Novartis AG, Santa Cruz Biotechnology Inc., Seagen Inc., Servier, and AbbVie Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this BCL-2 (B-cell Lymphoma 2) Inhibitors Market Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the BCL-2 (b-cell lymphoma 2) inhibitors market between 2023 and 2027
  • Precise estimation of the BCL-2 (b-cell lymphoma 2) inhibitors market size and its contribution to the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the industry across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive analysis of factors that will challenge the growth of bcl-2 (b-cell lymphoma 2) inhibitors market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global BCL-2 (B-cell lymphoma 2) inhibitors market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global BCL-2 (B-cell lymphoma 2) inhibitors market 2017 - 2021 ($ million)
    • 4.2 Product Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 ($ million)
    • 4.3 Type Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Type Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by Product

    • 6.1 Market segments
      • Exhibit 30: Chart on Product - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on Product - Market share 2022-2027 (%)
    • 6.2 Comparison by Product
      • Exhibit 32: Chart on Comparison by Product
      • Exhibit 33: Data Table on Comparison by Product
    • 6.3 Combination therapy - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Combination therapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Combination therapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Combination therapy - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Combination therapy - Year-over-year growth 2022-2027 (%)
    • 6.4 Monotherapy - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Monotherapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Monotherapy - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Monotherapy - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Monotherapy - Year-over-year growth 2022-2027 (%)
    • 6.5 Market opportunity by Product
      • Exhibit 42: Market opportunity by Product ($ million)
      • Exhibit 43: Data Table on Market opportunity by Product ($ million)

    7 Market Segmentation by Type

    • 7.1 Market segments
      • Exhibit 44: Chart on Type - Market share 2022-2027 (%)
      • Exhibit 45: Data Table on Type - Market share 2022-2027 (%)
    • 7.2 Comparison by Type
      • Exhibit 46: Chart on Comparison by Type
      • Exhibit 47: Data Table on Comparison by Type
    • 7.3 Diffuse large B-cell lymphoma (DLBCL) - Market size and forecast 2022-2027
      • Exhibit 48: Chart on Diffuse large B-cell lymphoma (DLBCL) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 49: Data Table on Diffuse large B-cell lymphoma (DLBCL) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 50: Chart on Diffuse large B-cell lymphoma (DLBCL) - Year-over-year growth 2022-2027 (%)
      • Exhibit 51: Data Table on Diffuse large B-cell lymphoma (DLBCL) - Year-over-year growth 2022-2027 (%)
    • 7.4 Follicular lymphoma - Market size and forecast 2022-2027
      • Exhibit 52: Chart on Follicular lymphoma - Market size and forecast 2022-2027 ($ million)
      • Exhibit 53: Data Table on Follicular lymphoma - Market size and forecast 2022-2027 ($ million)
      • Exhibit 54: Chart on Follicular lymphoma - Year-over-year growth 2022-2027 (%)
      • Exhibit 55: Data Table on Follicular lymphoma - Year-over-year growth 2022-2027 (%)
    • 7.5 Chronic lymphocytic leukemia - Market size and forecast 2022-2027
      • Exhibit 56: Chart on Chronic lymphocytic leukemia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 57: Data Table on Chronic lymphocytic leukemia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 58: Chart on Chronic lymphocytic leukemia - Year-over-year growth 2022-2027 (%)
      • Exhibit 59: Data Table on Chronic lymphocytic leukemia - Year-over-year growth 2022-2027 (%)
    • 7.6 Mantle cell lymphoma (MCL) - Market size and forecast 2022-2027
      • Exhibit 60: Chart on Mantle cell lymphoma (MCL) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 61: Data Table on Mantle cell lymphoma (MCL) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 62: Chart on Mantle cell lymphoma (MCL) - Year-over-year growth 2022-2027 (%)
      • Exhibit 63: Data Table on Mantle cell lymphoma (MCL) - Year-over-year growth 2022-2027 (%)
    • 7.7 Market opportunity by Type
      • Exhibit 64: Market opportunity by Type ($ million)
      • Exhibit 65: Data Table on Market opportunity by Type ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 67: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 69: Chart on Geographic comparison
      • Exhibit 70: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 Canada - Market size and forecast 2022-2027
      • Exhibit 91: Chart on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 92: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 93: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 94: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 9.9 Germany - Market size and forecast 2022-2027
      • Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.10 UK - Market size and forecast 2022-2027
      • Exhibit 99: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 100: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 101: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 102: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.11 France - Market size and forecast 2022-2027
      • Exhibit 103: Chart on France - Market size and forecast 2022-2027 ($ million)
      • Exhibit 104: Data Table on France - Market size and forecast 2022-2027 ($ million)
      • Exhibit 105: Chart on France - Year-over-year growth 2022-2027 (%)
      • Exhibit 106: Data Table on France - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 107: Market opportunity by geography ($ million)
      • Exhibit 108: Data Tables on Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 109: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 111: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 112: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 113: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 114: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Exhibit 115: AbbVie Inc. - Overview
              • Exhibit 116: AbbVie Inc. - Product / Service
              • Exhibit 117: AbbVie Inc. - Key news
              • Exhibit 118: AbbVie Inc. - Key offerings
            • 12.4 Abcam plc
              • Exhibit 119: Abcam plc - Overview
              • Exhibit 120: Abcam plc - Product / Service
              • Exhibit 121: Abcam plc - Key news
              • Exhibit 122: Abcam plc - Key offerings
            • 12.5 Amgen Inc.
              • Exhibit 123: Amgen Inc. - Overview
              • Exhibit 124: Amgen Inc. - Product / Service
              • Exhibit 125: Amgen Inc. - Key offerings
            • 12.6 Ascentage Pharma Group International
              • Exhibit 126: Ascentage Pharma Group International - Overview
              • Exhibit 127: Ascentage Pharma Group International - Product / Service
              • Exhibit 128: Ascentage Pharma Group International - Key offerings
            • 12.7 AstraZeneca Plc
              • Exhibit 129: AstraZeneca Plc - Overview
              • Exhibit 130: AstraZeneca Plc - Product / Service
              • Exhibit 131: AstraZeneca Plc - Key news
              • Exhibit 132: AstraZeneca Plc - Key offerings
            • 12.8 BeiGene Ltd.
              • Exhibit 133: BeiGene Ltd. - Overview
              • Exhibit 134: BeiGene Ltd. - Business segments
              • Exhibit 135: BeiGene Ltd. - Key offerings
              • Exhibit 136: BeiGene Ltd. - Segment focus
            • 12.9 Bio Techne Corp.
              • Exhibit 137: Bio Techne Corp. - Overview
              • Exhibit 138: Bio Techne Corp. - Business segments
              • Exhibit 139: Bio Techne Corp. - Key news
              • Exhibit 140: Bio Techne Corp. - Key offerings
              • Exhibit 141: Bio Techne Corp. - Segment focus
            • 12.10 Biorbyt Ltd.
              • Exhibit 142: Biorbyt Ltd. - Overview
              • Exhibit 143: Biorbyt Ltd. - Product / Service
              • Exhibit 144: Biorbyt Ltd. - Key offerings
            • 12.11 Bristol Myers Squibb Co.
              • Exhibit 145: Bristol Myers Squibb Co. - Overview
              • Exhibit 146: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 147: Bristol Myers Squibb Co. - Key news
              • Exhibit 148: Bristol Myers Squibb Co. - Key offerings
            • 12.12 F. Hoffmann La Roche Ltd.
              • Exhibit 149: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 150: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 151: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 152: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 153: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.13 Merck and Co. Inc.
              • Exhibit 154: Merck and Co. Inc. - Overview
              • Exhibit 155: Merck and Co. Inc. - Business segments
              • Exhibit 156: Merck and Co. Inc. - Key news
              • Exhibit 157: Merck and Co. Inc. - Key offerings
              • Exhibit 158: Merck and Co. Inc. - Segment focus
            • 12.14 Novartis AG
              • Exhibit 159: Novartis AG - Overview
              • Exhibit 160: Novartis AG - Business segments
              • Exhibit 161: Novartis AG - Key offerings
              • Exhibit 162: Novartis AG - Segment focus
            • 12.15 Santa Cruz Biotechnology Inc.
              • Exhibit 163: Santa Cruz Biotechnology Inc. - Overview
              • Exhibit 164: Santa Cruz Biotechnology Inc. - Product / Service
              • Exhibit 165: Santa Cruz Biotechnology Inc. - Key offerings
            • 12.16 Seagen Inc.
              • Exhibit 166: Seagen Inc. - Overview
              • Exhibit 167: Seagen Inc. - Product / Service
              • Exhibit 168: Seagen Inc. - Key offerings
            • 12.17 Servier
              • Exhibit 169: Servier - Overview
              • Exhibit 170: Servier - Business segments
              • Exhibit 171: Servier - Key offerings
              • Exhibit 172: Servier - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 173: Inclusions checklist
                • Exhibit 174: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 175: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 176: Research methodology
                • Exhibit 177: Validation techniques employed for market sizing
                • Exhibit 178: Information sources
              • 13.5 List of abbreviations
                • Exhibit 179: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              bcl-2 (b-cell lymphoma 2) inhibitors market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis